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The Continued Yin and Yang of Uric Acid
To the Editor:
We read with interest the recent research letter by Amaro et
al.1 Their analysis adds to the growing literature on uric acid
(UA) and vascular disease. However, their review of this nascent
literature was unbalanced, and we must challenge certain of their
statements of “fact”.
The “positive” effect of UA claimed by Amaro et al must be
balanced against established data suggesting a link between
increasing serum UA and cardiovascular disease.2–4 This rela-
tionship remains true for the acute infarct period.4,5 We have
previously shown4 that small increments in admission serum UA
are associated with significantly worse 90-day outcome. How-
ever, their group have previously suggested very different
findings—that increasing serum UA is associated with favorable
outcome at 7 days.6 This difference is intriguing. We do not
agree with the author’s comment that “confounders” may have
biased our results; if anything, our analysis is more robust, and at
the very least highly similar in technique to their own. We
thoroughly explored univariate differences in clinical features
between outcome groups and used multiple logistic regression to
control for factors known to influence outcome: including
baseline National Institutes of Health Stroke Scale score. We also
performed a further analysis where fully adjusted multiple Cox
proportional-hazards ratios revealed an increased risk of recur-
rent vascular events with increasing serum uric acid. We chose
an objective, reliable 90-day outcome (alive, placed in own home
or dead), which recent data suggest is closely related to 90-day
modified Rankin scale score.7 They used day-7 Mathew scale
score—this eponymous scale is poorly validated and has been all
but abandoned in the modern stroke literature.
We completely agree that the potential antioxidant properties
of serum UA are of interest, and we hope that they investigate
this further. Their data concerning lower-lipid peroxidation after
administration of UA are of particular interest. However, it is
important to acknowledge that the case for a pure antioxidant
property of serum UA is not completely made. Considerable data
suggest that UA is a conditional pro-oxidant. Also, although
animal data suggest that administration of serum UA can reduce
infarct volume,8 we must recall the dangers of direct extrapola-
tion from animal to human where neuroprotectant therapy is
concerned. This may particularly apply here; UA metabolism and
serum levels differ widely between species dependent on the
presence of the uricase enzyme, which is lacking in humans.
The increasingly conflicting data, where some suggest benefit
and others suggest harm from elevated serum UA, demand
thorough and thoughtful debate. It is entirely plausible that
chronic elevations in serum UA convey harm via detrimental
effects on endothelial function and smooth-muscle cell prolifer-
ation but that the potential antioxidant effects of UA itself can be
harnessed in acute ischemia and oxidative stress. In summary,
their data are promising; we hope to see further study, but it must
be acknowledged that more data concerning the effect of serum
UA on accepted “clinical trial standard” outcomes such as
90-day modified Rankin Scale are required. Equally, the STAIR
criteria, or perhaps the “New Roadmap for Neuroprotection”
must be followed.
Sources of Funding
M.W. and J.D. hold a research grant to aid investigation of uric
acid reduction as a secondary preventative strategy after stroke.
J.D. is funded by a Chest Heart Stroke Scotland Fellowship.
Disclosures
None.
Jesse Dawson, MRCP
Terry Quinn, MRCP
Kennedy Lees, MD, FRCP
Matthew Walters, MD, FRCP
Department of Cardiovascular and Medical Sciences
Western Infirmary Hospital
Glasgow, UK
1. Amaro S, Soy D, Obach V, Cervera A, Planas AM, Chamorro A. A pilot
study of dual treatment with recombinant tissue plasminogen activator and
uric acid in acute ischemic stroke. Stroke. 2007;38:2173.
2. Dawson J, Walters M. Uric acid and xanthine oxidase: future therapeutic
targets in the prevention of cardiovascular disease? B J Cl Pharm 2006;
62633–62644.
3. Dawson J, Quinn TQ, Walters MR. Xanthine oxidase inhibiton – A new
paradigm in management of cardiovascular risk. Current Medicinal
Chemistry. 2007;14:1879–1886.
4. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent
predictor of poor outcome and vascular events after acute stroke. Stroke.
2003;34:1951–1957.
5. Cherubini A, Polidori MC, Bregnocchi M, Pezzuto S, Cecchetti R, Ingegni
T, dilorio A, Senin U, Mecocci P. Antioxidant profile and early outcome
in stroke patients. Stroke. 2003;31:2295–2300.
6. Chamorro A, Obach V, Cervera A, Revilla M, Deulofeu R, Aponte JH.
Prognostic significance of uric acid serum concentration in patients with
acute ischaemic stroke. Stroke. 2002;33:1048–1052.
7. Dawson J, Lees JR, Chang TP, Walters MR, Ali M, Davis SM, Diener HC,
Lees KR. Relation between 3-month modified Rankin Scale score,
duration of institutional stay and estimated cost of care. Stroke. 2007;38:
1893–1898.
8. Yu ZF, Bruce-Keller AJ, Goodman Y, Mattson MP. Uric acid protects
neurons against excitotoxic and metabolic insults in cell culture, and
against focal ischaemic brain injury in vivo. J Neurosci Res. 1998;53:
613–625.
(Stroke. 2008;39:e9.)
© 2007 American Heart Association, Inc.
Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STROKEAHA.107.502245
e9
Letters to the Editor
